TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

The improvement in survival in the LSL-Kras G12D Tsc1 L /+ mice was somewhat less dramatic but still highly significant (6.9 vs. 16.3 weeks, p = 0.002), likely due in part to the slower tumor onset in LSL-Kras G12D Tsc1 L /+ mice.

also in 132,142 other papers